Advent International has agreed to buy Zentiva, Sanofi’s European generics business, for 1.9 billion euros ($2.37 billion). Advent will invest in the company’s operations, production facilities and R&D pipeline.
Press release
Advent International (“Advent”) and Sanofi have entered into exclusive negotiations under which Advent would acquire Zentiva, Sanofi’s European generics business for €1,919 million.
